Elanco Animal Health Incorporated
ELAN
Rank in Stocks
#1816
Elanco Animal Health, a firm dedicated to animal well-being, creates, produces,... Elanco Animal Health, a firm dedicated to animal well-being, creates, produces, and commercializes a diverse array of solutions for both companion animals and livestock. For household pets, the company provides preventative health solutions, including parasiticides and vaccinations, designed to guard against common ailments like worms, fleas, and ticks, with notable brands such as Seresto, Advantage, Advantix, and Advocate. Additionally, Elanco supplies therapeutic treatments for canine and feline conditions including pain, osteoarthritis, ear infections, cardiovascular issues, and dermatological problems, marketed under labels like Galliprant and Claro. Its portfolio for agricultural animals encompasses vaccines, antibiotics, parasiticides, and other essential products for poultry and aquaculture farming. This segment also features nutritional supplements such as enzymes, probiotics, and prebiotics to support animal health and growth. Furthermore, the company offers a comprehensive suite of products for ruminant and swine operations, comprising vaccines, antibiotics, implants, and parasiticides, often recognized by brands like Rumensin and Baytril. Elanco distributes its offerings through various channels, including independent distributors, veterinary clinics, and a broad spectrum of farm animal producers, from cattle and dairy farms to pig, poultry, and aquaculture enterprises. Established in 1954, Elanco Animal Health Incorporated maintains its corporate headquarters in Greenfield, Indiana.
Share Price
$23.51
Last synced: 2026-10-19
Market Cap
$11.74B
Change (1 day)
-0.15%
Change (1 year)
8.22%
Country
US
Trade Elanco Animal Health Incorporated (ELAN)
Category
Healthcare
P/E ratio for Elanco Animal Health Incorporated (ELAN)
P/E ratio as of October 2026 TTM: -55.00
According to Elanco Animal Health Incorporated latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -55.00. At the end of 2023 the company had a P/E ratio of -5.96.
P/E ratio history for Elanco Animal Health Incorporated from 2015 to 2026
P/E ratio at the end of each year
| Year | P/E Ratio | Change |
|---|---|---|
| 2026 (TTM) | -55.00 | -410.73% |
| 2024 | 17.70 | -397.03% |
| 2023 | -5.96 | -92.21% |
| 2022 | -76.50 | 167.23% |
| 2021 | -28.63 | 18.44% |
| 2020 | -24.17 | -115.10% |
| 2019 | 160.04 | 39.96% |
| 2018 | 114.35 | -377.06% |
| 2017 | -41.27 | -84.58% |
| 2016 | -267.71 | 340.08% |
| 2015 | -60.83 | 0.00% |
P/E ratio for similar companies or competitors
| Company | P/E Ratio | P/E Ratio Difference | Country |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| 34.96 | -163.56% |
IN
|
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.